

J.P. Morgan Healthcare Conference

RxSight® Adjustable IOL Technology

Ron Kurtz, CEO

January 15, 2025

Disclaimer & Forward-looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “forecast,” “budget,” and variations of such words or similar expressions. Statements of past performance, efforts or results, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of the RxSight, Inc. (“RxSight,” “we” or “us”) management as well as assumptions made by and information currently available to RxSight. Such statements reflect the current views of RxSight with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about RxSight. Such statements may include, without limitation, statements regarding (i) adoption trends and projections regarding the future volume of cataract surgical procedures and related revenue and the role of premium IOLs therein, (ii) estimates of RxSight’s addressable market opportunity and related growth, in the U.S. and globally, (iii) the efficacy of RxSight’s mechanisms and procedures, (iv) the performance of other premium and conventional IOLs compared to RxSight’s, (v) the number of patients eligible for LAL procedures, (vi) revenue associated with LAL procedures and the premium IOL market, (vii) statements regarding our future financial or business performance, (viii) the timing and success of our development and commercialization of our products, (ix) the continued acceptance of our products in the marketplace and our competitive positioning, (x) 2024 preliminary LDD installed base, LAL units sold and total revenue; (xi) anticipated continued growth based on RxSight adjustable innovation, and (xii) RxSight’s plans to enter international markets.

This presentation contains estimates, projections and other information concerning our business, our industry and the markets for our products, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this presentation from our internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources from which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies is subject to risks, uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information.

More details about these and other risks that may impact RxSight’s business are described under the heading “Risk Factors” in Part II, Item 1A of RxSight’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on November 7, 2024, and in subsequent filings with the SEC, which are available on the SEC’s website at www.sec.gov. RxSight cautions you not to place undue reliance on any forward-looking statement, which speaks only as of the date hereof. RxSight does not undertake any duty to update any forward-looking statement or other information in this presentation, except to the extent required by law.


A Paradigm Shift in Premium Cataract Surgery

RxSight Technology provides a better medicine/ better business approach

Drives a high growth, high margin, durable revenue model

Cloudy cataractous lens removed


Intraocular lens (IOL) implanted in place



Pre-Op Exam

Surgery

Post-Op



 Reimbursement

Standard Cataract Extraction with IOL Placement

Introduced 75 years ago, revolutionizing visual outcomes with monofocal IOLs

Most common surgical procedure in ophthalmology, low reimbursement

~32M global procedures annually, including ~5M in the U.S. ¹

Glasses for residual refractive errors:
• sphere, astigmatism, presbyopia

 Reimbursement +  Patient Pay

Premium Cataract Surgery with Fixed IOLs

Introduced 20 years ago, with goal of delivering better vision without glasses

~3–10x more practice revenue than standard IOL surgery ¹

~5M global procedures annually, including ~1M in the U.S. ¹

Despite limitations of current lenses

1. Market Scope 2024 Premium Cataract Surgery Market Report, October 2024

LAL Enables Better Medicine

The Light Adjustable Lens™ is the only customizable IOL for optimized vision without glasses



Choose LAL and approximate power

Streamlined patient discussions
Pre-operative measurements

Perform surgery



Real life trial drives LALs adjustments


Office-based light treatments designed to customize LAL to patient's optimal refraction using the RxSight Light Delivery Device™ (LDD™)

Patients experience their vision at home after light treatment, return to clinic for additional adjustments, or to make the prescription permanent




Light Treatments

The Ability to Adjust the Lens After Surgery Delivers Unmatched Refractive Precision



Other Lenses

LAL eyes have
14.5 X
better odds of achieving optimal visual outcomes (absolute MRSE and MRCyl \leq 0.50 D)¹




LAL

1. Data on file - RxSight Post-Approval Study

Refractive Precision Enables Doctors to Efficiently Optimize Vision in Both Eyes

Vast majority of patients have cataract surgery in both eyes

RxSight enables seamless bilateral approach to customize visual outcomes.




1. Erie, E et al (2022). Prevalence of pseudophakia: U.S. population-based study. JCRS: 48; 717-722

Refractive Precision Enables Doctors to Efficiently Optimize Vision in Both Eyes

Vast majority of patients have cataract surgery in both eyes

RxSight enables seamless bilateral approach to customize visual outcomes.



High-Quality Vision Using Both Eyes

1. Erie, E et al (2022). Prevalence of pseudophakia: U.S. population-based study. JCRS: 48; 717-722

Growing Data Set and Clinical Consensus

Real world data from over 3,000 eyes ¹

ACCURACY

>94%

+/- MRSE ¹

OUTCOMES

>90%

20/25 distance and
J2 near without
glasses ¹

LAL Customer Survey

92%

believe LAL provides
highest quality of
vision ²

82%

would select for their
own premium IOL
surgery (vs 11% for
multifocal and 7%
EDOF) ²

1. RxSight Data on File: PMCS-002
2. 2024 RxSight Customer Survey

LAL Enables Better Business

Boosting profitability through premium IOL adoption

Enables more doctors and practices to participate in premium IOL segment

Allows more patients to choose a premium IOL

In RxSight customer survey, 40% of LAL patients would have received a non-premium IOL ¹




1. Haffey & Company 2024 Economic Study of LAL Users


RxSight's Track Record of Success

Building Infrastructure for Postoperative Adjustability

LDD Installed Base



LAL Units



Total Revenue (in millions)




* Preliminary unaudited total

A Future of Premium Cataract Surgery with Adjustability

US Cataract Surgery CAGR of ~3% ¹

US Premium Cataract Surgery Growth from 20% to ~35% of overall cataract procedures

Adjustable becomes standard within Premium (\geq 50% market share) driving segment growth




1. Market Scope 2024 IOL Report, March 2024

Expanding Access to Adjustability


Evolving care delivery and innovative business models to expand access to adjustability




Practice A
Surgeon Office
with LDD


Practice A
Surgeon Office
No LDD


**LDD Treatment
Center**


Practice B
Surgeon Office
No LDD



Practice C
Surgeon Office
No LDD


Practice D
Surgeon Office
No LDD



Providing access to **more patients** and **more implanters**

Continued Innovations in Adjustability

Advancements drive further adoption



Bringing the RxSight System to International Markets




Key OUS markets make up >80% of global procedures with growing procedure potential ¹

1. Market Scope 2024 Premium Cataract Surgery Market Report, October 2024

Thank you!

Light 
Adjustable
Lens™



Light 
Adjustable
Lens+™

RxSight® Adjustable IOL Technology
New Global Standard for Premium Cataract Surgery